Business Standard

Cadila Healthcare's Q4 PBT falls 14% to Rs 522 cr, total income rises 0.66%

Cadila has also been working on a DNA vaccine to fight Covid-19, which is currently in the animal testing stage

Cadila Healthcare
Premium

Zydus, which is also involved in developing a vaccine against the coronavirus, will now also get to manufacture and distribute Remdesivir.

Vinay Umarji Ahmedabad
Drug maker Cadila Healthcare Ltd (Zydus Cadila) reported a consolidated profit before tax (PBT) of Rs 522 crore for the quarter ended March 31, 2020, down 13.84 per cent over the corresponding quarter last year. In Q4FY19, the company's consolidated PBT stood at Rs 605.9 crore.
 
The company's consolidated total income for Q4FY20 grew marginally by 0.66 per cent to Rs 3,796.4 crore, up from Rs 3771.2 crore in corresponding period of the previous fiscal. For the entire fiscal 2019-20 (FY20), Zydus Cadila saw its consolidated PBT fall by 37.22 per cent to stand at Rs 1495.4 crore, down from

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 19 2020 | 5:29 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com